Among global leaders in healthcare innovation at the Precision Medicine World Conference 2025, Allelica CEO Giordano Bottà will present how clinical multi-ancestry polygenic risk score testing empowers physicians to prevent heart attacks.

Allelica has officially received its CLIA number, marking a key milestone in delivering clinically validated genetic testing. This certification enables the company to offer high-quality polygenic risk score testing for improved patient care.

At ASHG 2024, Allelica introduced its innovative approach to modeling human genetic diversity without labels - the “8 billion method” - enhancing equity in precision medicine. This breakthrough improves polygenic risk score performance across diverse populations, reducing bias in genetic risk assessment.

Allelica’s PRS software and reports are now compatible with Thermo Fisher Scientific’s Axiom™ human genotyping arrays. This integration streamlines PRS implementation, enabling more efficient and scalable genetic risk assessment for clinical and research applications.

Allelica will provide its multi-ancestry polygenic risk score (PRS) technology to Baylor College of Medicine for clinical implementation. This collaboration advances precision medicine by integrating PRS into patient care, improving risk assessment across diverse populations.

Results published by Allelica scientists in Nature Communications demonstrate the clinical utility of polygenic risk scores across multiple ancestry groups.The publication adds to growing evidence of the clinical value of PRS in cardiovascular disease risk assessment, showing that adding PRS to traditional models improves their precision and accuracy.

Allelica presented collaborative results with Baylor College of Medicine at the American Society of Human Genetics Annual Meeting 2023. George Busby, Allelica CSO, presented the results in the poster titled “Complete end-to-end workflow for implementing clinical polygenic risk scores”.

Allelica announces the release of the Allelica Precision Server (APS) for CLIA-compliant, on-premises analysis and clinical reporting of polygenic risk score, pharmacogenomics and carrier screening. APS is now available for medical laboratories and healthcare providers.

The Allelica team met with leaders in the pharmaceutical industry and biotechnology at the annual BioTechX conference in Basel, Switzerland. PRS is increasingly gaining traction among pharma and biotech companies for its ability to stratify clinical trial populations and identify new drug targets.

Results published by Allelica researchers in Frontiers in Public Health reveal that integrating PRS testing into workplace health programs cuts costs for employers and improves quality of life for employees. Authors found that Allelica's workplace program integrating PRS with the standard of care, cardioriskSCORE, significantly outperformed programs without PRS.

The Allelica team showcased exciting PRS results at the European Society of Human Genetics Conference 2023. Posters included: Low-coverage genotyping-by-sequencing with accurate long HiFi reads and optimized imputation (presented in collaboration with PacBio), Recalibrating polygenic risk scores to country-specific incidence, and Analyses of polygenic risk scores that consider individual-level admixture proportions outperform single ancestry approaches.

Dr. Daniel Morganstern of Hartford Healthcare presented results integrating Allelica’s multi-ancestry PRSs into risk assessments at the American Society of Clinical Oncology Annual Meeting. Findings revealed the value PRS provides in clinical risk assessments for breast cancer.

A health economics study [Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk‐Enhancing Factor in the Pooled Cohort Equation: A Cost‐Effectiveness Analysis Study] has been published in the Journal of the American Heart Association. The study, performed by Allelica, in collaboration with experts from Illumina and the University of Sydney, analyzed the cost-effectiveness of PRS in heart disease risk assessments and found that PRS is cost-saving in US health systems.

Allelica researchers identified a critical interaction between PRS for coronary artery disease (CAD) and LDL cholesterol level. Their discovery has major implications for clinical decision-making in primary prevention strategies. The research is now available in the American Heart Association Journal, Circulation.

Allelica continues to set the industry standard of clinical-grade Polygenic Risk Score analysis with the addition of two key ISO certifications. ISO 13485 and ISO 9001 certify that Allelica applies medical device quality management processes every step of the way.